Undecimal Bio

Onepot, founded in 2023 in South San Francisco, USA, synthesizes small molecules for drug discovery using AI-driven automated synthesis for biopharmaceutical companies.

Seed · $13M · 2025-11

Pepper Bio, founded in 2018 in Massachusetts, USA, analyzes multi-layered biological data—including DNA, RNA, proteomic, and phosphoproteomic data—to discover novel drug candidates.

Seed · $7M · 2023-12

Iambic Therapeutics (formerly Entos), founded in 2019 in San Diego, uses artificial intelligence to predict protein-ligand structures and generate molecular designs for the discovery of new drugs.

IPO · $462M · 2026-09

NeuShen Therapeutics, founded in 2022 by Dr. Joan Huaqiong Shen, is a clinical-stage international biotech company headquartered in Shanghai with an R&D center in Boston, dedicated to innovative therapies for psychiatric and neurological disorders through its NeuChime small-molecule discovery platform and NeuGem AAV gene therapy platform. Its pipeline includes NS-136 (an M4 positive allosteric modulator for schizophrenia and Alzheimer's-related agitation, in clinical trials in Australia) and NS-041 (a KCNQ2/3 activator for focal-onset seizures and major depressive disorder, IND accepted by China's CDE in December 2023).

Series B · 2026-09

Insilico Medicine, founded in 2019 in Shanghai, China, is a developer of drug candidates for anti-aging and cancer treatment.

Series D+ · $210M · 2025-03

Nutshell Therapeutics (Shanghai Yudao Biotechnology), founded in 2013 in Shanghai, develops allosteric small-molecule drugs for hard-to-drug targets using its AlloMatrix allosteric database and AlloStar AI+physics platform; its p53 Y220C reactivator NTS071 is in a global Phase I trial.

Series C · 2026-09

Isomorphic Labs is a drug discovery company spun out of DeepMind and founded in 2022 in London, applying AI to drug discovery and design including protein structure prediction via AlphaFold.

Series B · $2.7B · 2026-05

Cyclana Bio, founded in 2025 in Cambridge, UK, develops tissue-level drug discovery models for the treatment of endometriosis.

Pre-Seed · $7M · 2025-10

AI-native drug discovery using patient-derived disease models to design small-molecule therapies for cancer and fibrosis.

Pre-Seed · $3M · 2026-07

Deep Cell is an AI-pharma and virtual-cell startup whose core approach deeply fuses 'AI + multi-scale physical mechanics'. Built around a molecular-interaction foundation model, it develops a high-precision molecular-design platform and a virtual-cell world model spanning a unified 'multi-omics - structure - interaction - energy - dynamics - function' framework, aiming to link scales from molecules to pathways and from local cell states to whole-cell states and disease phenotypes. Founder Chen Xindong holds a Tsinghua doctorate under academician Feng Xiqiao, with work published in PNAS and ACS Nano. The company is an early-stage platform with undisclosed pipelines.

Seed · $14M · 2026-08

According to a TechCrunch report dated July 14, 2026 (source unspecified), former OpenAI researcher Miles Wang is preparing to launch an AI drug discovery startup. The company name, headquarters, and website remain undisclosed, and the funding details are unconfirmed rumors.

Galux, founded in 2020 in Seoul, operates GaluxDesign, an AI and physics-based platform for protein and antibody design in drug development.

Series B · $58M · 2026-02